Karamali, M. and Bahramimoghadam, S. and Sharifzadeh, F. and Asemi, Z. (2018) Magnesium�zinc�calcium�vitamin d co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: A randomized, double-blind, placebo-controlled trial. Applied Physiology, Nutrition and Metabolism, 43 (6). pp. 565-570.
Full text not available from this repository.Abstract
To the best our knowledge, data on the effects of magnesium�zinc�calcium�vitamin D co-supplementation on glycemic control and markers of cardiometabolic risk in gestational diabetes mellitus (GDM) are scarce. The purpose of this study was to establish the effects of magnesium�zinc�calcium�vitamin D co-supplementation on glycemic control and markers of cardiometabolic risk of GDM patients. Sixty patients with GDM, aged 18�40 years, were randomized into 2 groups to intake either magnesium�zinc�calcium�vitamin D co-supplements or placebo (n = 30 each group) for 6 weeks in a randomized, double-blind, placebo-controlled trial. Fasting blood samples were taken at baseline and week 6 to quantify related markers. After the 6-week intervention, compared with the placebo, magnesium�zinc�calcium�vitamin D co-supplementation resulted in significant reductions in fasting plasma glucose (�0.37 ± 0.09 vs. +0.01 ± 0.09 mmol/L, P = 0.003), serum insulin levels (�21.0 ± 4.8 vs. +7.2 ± 4.8 pmol/L, P < 0.001), homeostatic model of assessment for insulin resistance (�1.0 ± 1.1 vs. +0.3 ± 1.3, P < 0.001), and a significant increase in quantitative insulin sensitivity check index (+0.02 ± 0.03 vs. �0.002 ± 0.03, P = 0.003). In addition, magnesium�zinc�calcium�vitamin D co-supplementation significantly decreased serum triglycerides (�0.25 ± 0.10 vs. +0.34 ± 0.10 mmol/L, P = 0.001) and very-low-density�cholesterol concentrations (�0.11 ± 0.04 vs. +0.15 ± 0.04 mmol/L, P = 0.001) compared with the placebo. Overall, the results of this study demonstrated that magnesium�zinc�calcium�vitamin D co-supplementation for 6 weeks among patients with GDM had beneficial effects on glycemic control and few markers of cardiometabolic risk. © 2018, Canadian Science Publishing. All rights reserved.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 1 |
| Depositing User: | eprints admin |
| Date Deposited: | 05 Aug 2018 03:23 |
| Last Modified: | 05 Aug 2018 03:23 |
| URI: | http://eprints.iums.ac.ir/id/eprint/831 |
Actions (login required)
 |
View Item |
